Home » Stocks » ATRS

Antares Pharma, Inc. (ATRS)

Stock Price: $4.45 USD -0.02 (-0.45%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 753.68M
Revenue (ttm) 158.60M
Net Income (ttm) 62.35M
Shares Out 167.82M
EPS (ttm) 0.36
PE Ratio 12.54
Forward PE 33.44
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $4.45
Previous Close $4.47
Change ($) -0.02
Change (%) -0.45%
Day's Open 4.49
Day's Range 4.43 - 4.50
Day's Volume 481,690
52-Week Range 2.55 - 5.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The FDA has accepted Antares Pharma Inc's (NASDAQ: ATRS) Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue.  The active IND enables Antares to initiate a Phase 1 study f...

1 week ago - Benzinga

EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) h...

1 week ago - GlobeNewsWire

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

Other stocks mentioned: GTBP, OBSV, OCGN, ODT, PTN, SEEL
3 weeks ago - PennyStocks

EWING, N.J., June 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that it has submitted an Investigational New Drug ...

1 month ago - GlobeNewsWire

EWING, N.J., June 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executiv...

1 month ago - GlobeNewsWire

EWING, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive...

2 months ago - GlobeNewsWire

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 2.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice P...

2 months ago - GlobeNewsWire

Increased Revenue 27% Year-Over-Year to $42.1 Million

2 months ago - GlobeNewsWire

EWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of...

2 months ago - GlobeNewsWire

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

EWING, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced it will release its first quarter 2021 financial ...

3 months ago - GlobeNewsWire

EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Exe...

3 months ago - GlobeNewsWire

In my opinion, choosing U.S.-listed securities that have the following characteristics represents a solid starting point when looking for potential value opportunities:

Other stocks mentioned: HLF, THRY
3 months ago - GuruFocus

Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the...

4 months ago - Benzinga

EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

5 months ago - GlobeNewsWire

EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year ...

5 months ago - GlobeNewsWire

EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

5 months ago - GlobeNewsWire

These interesting low-cost stocks have the opportunity to grow.

Other stocks mentioned: FLNT, OPK
7 months ago - The Motley Fool

These companies offer more potential than the stock price might indicate.

Other stocks mentioned: NOK, GSKY
8 months ago - The Motley Fool

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

8 months ago - GlobeNewsWire

EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

8 months ago - GlobeNewsWire

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
8 months ago - Seeking Alpha

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020 financial ...

9 months ago - GlobeNewsWire

Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19.

9 months ago - Seeking Alpha

Antares Expands Urology Portfolio and Leverages Commercial Organization Antares Expands Urology Portfolio and Leverages Commercial Organization

9 months ago - GlobeNewsWire

EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Exec...

10 months ago - GlobeNewsWire

Jack Howarth Retires as Vice President of Corporate Affairs Jack Howarth Retires as Vice President of Corporate Affairs

11 months ago - GlobeNewsWire

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q2 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
11 months ago - Seeking Alpha

Antares Pharma (NASDAQ: ATRS) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia.

11 months ago - Benzinga

EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with...

11 months ago - GlobeNewsWire

EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the Compan...

1 year ago - GlobeNewsWire

EWING, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the position...

1 year ago - GlobeNewsWire

Antares Continues To Quietly Grow Revenue

1 year ago - Seeking Alpha

EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ray...

1 year ago - GlobeNewsWire

Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?

1 year ago - The Motley Fool

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
1 year ago - Seeking Alpha

First-quarter financial results failed to spark investors' animal spirits.

1 year ago - The Motley Fool

Antares Pharma: An Undervalued Stock To Buy During The COVID-19 Crisis

1 year ago - Seeking Alpha

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
1 year ago - Seeking Alpha

Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.

1 year ago - The Motley Fool

Antares Pharma: Reasonable Expectations For 2020

1 year ago - Seeking Alpha

Antares Pharma: XYOSTED's Prescription Growth Is Running On All Cylinders

1 year ago - Seeking Alpha

The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance

1 year ago - GlobeNewsWire

Investors are locking in gains in this fast-growing drugmaker.

1 year ago - The Motley Fool

EWING, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. ...

1 year ago - GlobeNewsWire

About ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active r... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Oct 2, 1996
CEO
Robert Apple
Employees
185
Stock Exchange
NASDAQ
Ticker Symbol
ATRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Antares Pharma stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 46.07% from the latest price.

Price Target
$6.50
(46.07% upside)
Analyst Consensus: Strong Buy